Latest Road Tenders

TRID : 11185867 Actual Tender Number :

AOC

Contract awarded for Completion of a non-exclusive discount agreement according to § 130a para. 8 SGB V for the active ingredient dexamethasone (except implant), ATC S01BA01 for the time 01.01.2025 - 31.12.2026 Section 130a paragraph 8 SGB V enables health insurance companies and pharmaceutical companies to include framework discount contracts for the drugs to be issued at the expense of the statutory health insurance companies. With regard to the relevant legal regulations on the awarding of public orders, a regular process of active ingredient, formal award procedures takes place according to the regulations of the 4th part of the GWB through DAK health. For medicines to be named by the bidder in Appendix 2 to the contract to the above. Active ingredient dexamethasone (except implant), ATC S01BA01, intends to complete the DAK health until the entry into force of new pharmaceutical discount contracts with all interested pharmaceutical companies. A discount contract i.r.d. Admission model for the above. The active ingredient comes into force on 01.01.2025 for the first time and ends on December 31, 2026. It ends automatically with the entry into force of the exclusive contract. Value of the result: Winner selection date : 01/01/2025 Date of conclusion of the contract :01/01/2025 Offizielle Bezeichnung: OmniVision GmbH Größe des Wirtschaftsteilnehmers: Großunternehmen Registrierungsnummer: HRB 148982 Stadt: Puchheim Postleitzahl: 82178 Land, Gliederung (NUTS): Fürstenfeldbruck (DE21C) Land: Deutschland E-Mail: controlling@omnivision.de Telefon: +49 89840792-653 Rollen dieser Organisation: Bieter Federführendes Mitglied, Offizielle Bezeichnung: Immedica Pharma AB Größe des Wirtschaftsteilnehmers: Großunternehmen Registrierungsnummer: 556835-632 Stadt: Stockholm Postleitzahl: 11363 Land, Gliederung (NUTS): Hamburg (DE600) Land: Schweden E-Mail: info@immedica.com Telefon: +46 853339-500 Rollen dieser Organisation: Bieter, Offizielle Bezeichnung: TRB Chemedica AG Größe des Wirtschaftsteilnehmers: Mittleres Unternehmen Registrierungsnummer: HRB 114049 Stadt: Feldkirchen Postleitzahl: 85622 Land, Gliederung (NUTS): Landshut, Kreisfreie Stadt (DE221) Land: Deutschland E-Mail: info@trbchemedica.com Telefon: +49 2404553-389 Rollen dieser Organisation: Bieter, Offizielle Bezeichnung: Pharmaselect Deutschland GmbH Größe des Wirtschaftsteilnehmers: Kleinstunternehmen Registrierungsnummer: DE366736671 Stadt: Hannover Postleitzahl: 30159 Land, Gliederung (NUTS): Region Hannover (DE929) Land: Deutschland E-Mail: office@pharmaselect.com Telefon: +49 5117110900-532 Rollen dieser Organisation: BieterLOT-0001:Title: Completion of a non-exclusive discount agreement according to § 130a para. 8 SGB V for the active ingredient dexamethasone (except implant), ATC S01BA01 for the time 01.01.2025 - 31.12.2026 LOT-0001:Description: The DAK health assumes that this procedure does not fall into the scope of the antitrust deficiency law due to a lack of selection decision and therefore the possibility of discriminatory access of all pharmaceutical companies. Regardless of this, it automatically ends with the entry into force of the exclusive contract with Dexamethason (except implant), ATC S01BA01, as a result of a formal award procedure according to the regulations of the 4th part of the GWB with one or more contractual partners. In order to meet the diversity of the potential contractual partners within the framework of the approval model, every pharmaceutical company will be enabled to conclude a framework contract at any time and on the same conditions during the contract term. The contract documents required for this can be found on the online portal www.dtvp.de/center on 5.1.11. mentioned link for download. Requirements for the conclusion or the later accession to the contracts that have been entered for the first time on 01.01.2025 are the complete and timely sending of the following documents (available for download on the link mentioned under 5.1.11.) To the following department in the DAK-Gesundheit: 1. Submission of the contract with name or company stamp by the prospect at the intended body. 3. The completed systems 1 and 2 to the contract. The prospect must enter the drugs for the above -mentioned active ingredient, which should become subject to the contract. The documents must be submitted by email at: openhouse@dak.de DAK-Gesundheit Department of Medicines (0038 00) Nagelsweg 27-31 20097 Hamburg The Appendix 2 is expressly sent to the e-mail address openhouse@dak.de. Contracts within the framework of this model and the above. Interested parties who want to become a contractual partner for this date must submit the above-mentioned documents by email until 5. The previous month. The offer is to be submitted in text form as an electronic offer by email at openhouse@dak.de. The submission of the offer by post is not provided in this procedure. Please do not submit the offer via the German award portal. An electronic input of the complete documents by email to the email address openhouse@dak.de is sufficient for the deadline. Later joining is possible at any time. In order to be able to join the 1st or 15th of the following month during the term of the contract, the above documents, regardless of the desired accession, must be available to the DAK health up to the 5th month. Here, too, it depends on the timely access by email at the DAK-G. Example: The accession desired by the bidder should be on July 15th. (Consequences), the documents should be done until 05.06. (previous month). Note: The publication takes place here using the form for open procedures. As already made clear, this is not one - the announcement had to be used for technical reasons, since there is no form suitable for admission procedures. .Completion of a non-exclusive discount agreement according to § 130a para. 8 SGB V for the active ingredient dexamethasone (except implant), ATC S01BA01 for the time 01.01.2025 - 31.12.2026 at Not Classified,Not Classified,Germany